

Vertigo Treatment Market By Type (Peripheral Vertigo, Central Vertigo), By Treatment (Anticholinergics, Antihistamines, Others), By Distribution channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-09-01 | 310 pages | Allied Market Research

AVAILABLE LICENSES:

- Cloud Access License \$3456.00
- Business User License \$5481.00
- Enterprise License \$9450.00

Report description:

The global vertigo treatment market was valued at \$1,258.33 million in 2021, and is projected to reach \$1,938.47 million by 2031, registering a CAGR of 4.4% from 2022 to 2031.

A person with vertigo experiences the illusion that the items around him are moving when they are still. Sweating, nausea, vomiting, difficulty in walking, and loss of balance are common symptoms of the illness. The most common cause of vertigo is benign paroxysmal positional vertigo (BPPV). There are two types of vertigo, namely peripheral and central. For instance, peripheral vertigo is caused by a problem with vestibular system and due to motion sickness. Central vertigo is caused due to central nervous system injuries. Furthermore, the treatments for vertigo are prescribed depending upon the type and severity of symptoms. For instance, medications include anticholinergics, antihistamines, beta-blockers, and anticonvulsants.

The growth of the global vertigo treatment market is majorly driven by increase in prevalence of vertigo, rise in geriatric population as vertigo incidences increase with age, rise in awareness about inner ear problems, availability of vertigo medications, and initiatives taken by government to develop better healthcare infrastructure. For instance, according to National Library of Medicine, around 15%-20% adults are affected by vertigo every year. Moreover, rise in brain injuries, viral infections, and heart diseases contribute towards the market growth.

However, ignorance towards symptoms of vertigo, side effects associated with antivertigo medications, lack of standard tools for diagnosis in some regions, and high research and development costs hinders the market growth.

The vertigo treatment market is segmented into type, treatment, distribution channel, and region. By type, the market is categorized into peripheral vertigo and central vertigo. On the basis of treatment, the market is segregated into anticholinergics, antihistamines, and others. By distribution channel, the market is classified into hospital pharmacies, drug stores and retail

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

pharmacies (prescription drugs and OTC drugs), and online providers. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). Major key players that operate in the global vertigo treatment market are Amneal Pharmaceuticals Ltd., AstraZeneca Plc., Epic Pharma, LLC, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ag, Intas Pharmaceuticals Ltd, Novartis Ag, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Ltd., and Viartis (Mylan N.V.).

Key Benefits For Stakeholders

- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vertigo treatment market analysis from 2021 to 2031 to identify the prevailing vertigo treatment market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the vertigo treatment market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global vertigo treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

- Peripheral Vertigo
- Central Vertigo

By Treatment

- Anticholinergics
- Antihistamines
- Others

By Distribution channel

- Hospital Pharmacies
- Drug Stores Retail Pharmacies
- Prescription Type
- Prescription Drugs
- OTC Drugs
- Online Providers

By Region

- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- AstraZeneca plc.
- Endo Pharmaceuticals Inc
- Epic Pharma, LLC
- GlaxoSmithKline plc.
- Hoffmann-La Roche
- Novartis AG
- Pfizer Inc.
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Ltd.
- Viatris (Mylan N.V.)
- Zydus Cadila

Table of Contents:

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
- 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
 - 3.5.1.Drivers
 - 3.5.2.Restraints
 - 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

CHAPTER 4: VERTIGO TREATMENT MARKET, BY TYPE

4.1 Overview

4.1.1 Market size and forecast

4.2 Peripheral Vertigo

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market analysis by country

4.3 Central Vertigo

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market analysis by country

CHAPTER 5: VERTIGO TREATMENT MARKET, BY TREATMENT

5.1 Overview

5.1.1 Market size and forecast

5.2 Anticholinergics

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market analysis by country

5.3 Antihistamines

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market analysis by country

5.4 Others

5.4.1 Key market trends, growth factors and opportunities

5.4.2 Market size and forecast, by region

5.4.3 Market analysis by country

CHAPTER 6: VERTIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview

6.1.1 Market size and forecast

6.2 Hospital Pharmacies

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market analysis by country

6.3 Drug Stores & Retail Pharmacies

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market analysis by country

6.3.4 Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type

6.3.4.1 Prescription Drugs Market size and forecast, by region

6.3.4.2 OTC Drugs Market size and forecast, by region

6.4 Online Providers

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market analysis by country

CHAPTER 7: VERTIGO TREATMENT MARKET, BY REGION

7.1 Overview

7.1.1 Market size and forecast

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.2 North America
 - 7.2.1 Key trends and opportunities
 - 7.2.2 North America Market size and forecast, by Type
 - 7.2.3 North America Market size and forecast, by Treatment
 - 7.2.4 North America Market size and forecast, by Distribution channel
 - 7.2.4.1 North America Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
 - 7.2.5 North America Market size and forecast, by country
 - 7.2.5.1 U.S.
 - 7.2.5.1.1 Market size and forecast, by Type
 - 7.2.5.1.2 Market size and forecast, by Treatment
 - 7.2.5.1.3 Market size and forecast, by Distribution channel
 - 7.2.5.2 Canada
 - 7.2.5.2.1 Market size and forecast, by Type
 - 7.2.5.2.2 Market size and forecast, by Treatment
 - 7.2.5.2.3 Market size and forecast, by Distribution channel
 - 7.2.5.3 Mexico
 - 7.2.5.3.1 Market size and forecast, by Type
 - 7.2.5.3.2 Market size and forecast, by Treatment
 - 7.2.5.3.3 Market size and forecast, by Distribution channel
- 7.3 Europe
 - 7.3.1 Key trends and opportunities
 - 7.3.2 Europe Market size and forecast, by Type
 - 7.3.3 Europe Market size and forecast, by Treatment
 - 7.3.4 Europe Market size and forecast, by Distribution channel
 - 7.3.4.1 Europe Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
 - 7.3.5 Europe Market size and forecast, by country
 - 7.3.5.1 Germany
 - 7.3.5.1.1 Market size and forecast, by Type
 - 7.3.5.1.2 Market size and forecast, by Treatment
 - 7.3.5.1.3 Market size and forecast, by Distribution channel
 - 7.3.5.2 France
 - 7.3.5.2.1 Market size and forecast, by Type
 - 7.3.5.2.2 Market size and forecast, by Treatment
 - 7.3.5.2.3 Market size and forecast, by Distribution channel
 - 7.3.5.3 UK
 - 7.3.5.3.1 Market size and forecast, by Type
 - 7.3.5.3.2 Market size and forecast, by Treatment
 - 7.3.5.3.3 Market size and forecast, by Distribution channel
 - 7.3.5.4 Italy
 - 7.3.5.4.1 Market size and forecast, by Type
 - 7.3.5.4.2 Market size and forecast, by Treatment
 - 7.3.5.4.3 Market size and forecast, by Distribution channel
 - 7.3.5.5 Spain
 - 7.3.5.5.1 Market size and forecast, by Type
 - 7.3.5.5.2 Market size and forecast, by Treatment
 - 7.3.5.5.3 Market size and forecast, by Distribution channel
 - 7.3.5.6 Rest of Europe

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.3.5.6.1 Market size and forecast, by Type
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by Distribution channel
- 7.4 Asia-Pacific
 - 7.4.1 Key trends and opportunities
 - 7.4.2 Asia-Pacific Market size and forecast, by Type
 - 7.4.3 Asia-Pacific Market size and forecast, by Treatment
 - 7.4.4 Asia-Pacific Market size and forecast, by Distribution channel
 - 7.4.4.1 Asia-Pacific Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
 - 7.4.5 Asia-Pacific Market size and forecast, by country
 - 7.4.5.1 Japan
 - 7.4.5.1.1 Market size and forecast, by Type
 - 7.4.5.1.2 Market size and forecast, by Treatment
 - 7.4.5.1.3 Market size and forecast, by Distribution channel
 - 7.4.5.2 China
 - 7.4.5.2.1 Market size and forecast, by Type
 - 7.4.5.2.2 Market size and forecast, by Treatment
 - 7.4.5.2.3 Market size and forecast, by Distribution channel
 - 7.4.5.3 Australia
 - 7.4.5.3.1 Market size and forecast, by Type
 - 7.4.5.3.2 Market size and forecast, by Treatment
 - 7.4.5.3.3 Market size and forecast, by Distribution channel
 - 7.4.5.4 India
 - 7.4.5.4.1 Market size and forecast, by Type
 - 7.4.5.4.2 Market size and forecast, by Treatment
 - 7.4.5.4.3 Market size and forecast, by Distribution channel
 - 7.4.5.5 South Korea
 - 7.4.5.5.1 Market size and forecast, by Type
 - 7.4.5.5.2 Market size and forecast, by Treatment
 - 7.4.5.5.3 Market size and forecast, by Distribution channel
 - 7.4.5.6 Rest of Asia-Pacific
 - 7.4.5.6.1 Market size and forecast, by Type
 - 7.4.5.6.2 Market size and forecast, by Treatment
 - 7.4.5.6.3 Market size and forecast, by Distribution channel
 - 7.5 LAMEA
 - 7.5.1 Key trends and opportunities
 - 7.5.2 LAMEA Market size and forecast, by Type
 - 7.5.3 LAMEA Market size and forecast, by Treatment
 - 7.5.4 LAMEA Market size and forecast, by Distribution channel
 - 7.5.4.1 LAMEA Drug Stores & Retail Pharmacies Vertigo Treatment Market by Prescription Type
 - 7.5.5 LAMEA Market size and forecast, by country
 - 7.5.5.1 Brazil
 - 7.5.5.1.1 Market size and forecast, by Type
 - 7.5.5.1.2 Market size and forecast, by Treatment
 - 7.5.5.1.3 Market size and forecast, by Distribution channel
 - 7.5.5.2 Saudi Arabia
 - 7.5.5.2.1 Market size and forecast, by Type

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by Distribution channel
- 7.5.5.3 South Africa
 - 7.5.5.3.1 Market size and forecast, by Type
 - 7.5.5.3.2 Market size and forecast, by Treatment
 - 7.5.5.3.3 Market size and forecast, by Distribution channel
- 7.5.5.4 Rest of LAMEA
 - 7.5.5.4.1 Market size and forecast, by Type
 - 7.5.5.4.2 Market size and forecast, by Treatment
 - 7.5.5.4.3 Market size and forecast, by Distribution channel

CHAPTER 8: COMPANY LANDSCAPE

- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

- 9.1 AstraZeneca plc.
 - 9.1.1 Company overview
 - 9.1.2 Company snapshot
 - 9.1.3 Operating business segments
 - 9.1.4 Product portfolio
 - 9.1.5 Business performance
 - 9.1.6 Key strategic moves and developments
- 9.2 Endo Pharmaceuticals Inc
 - 9.2.1 Company overview
 - 9.2.2 Company snapshot
 - 9.2.3 Operating business segments
 - 9.2.4 Product portfolio
 - 9.2.5 Business performance
 - 9.2.6 Key strategic moves and developments
- 9.3 Epic Pharma, LLC
 - 9.3.1 Company overview
 - 9.3.2 Company snapshot
 - 9.3.3 Operating business segments
 - 9.3.4 Product portfolio
 - 9.3.5 Business performance
 - 9.3.6 Key strategic moves and developments
- 9.4 GlaxoSmithKline plc.
 - 9.4.1 Company overview
 - 9.4.2 Company snapshot
 - 9.4.3 Operating business segments
 - 9.4.4 Product portfolio
 - 9.4.5 Business performance
 - 9.4.6 Key strategic moves and developments
- 9.5 Hoffmann-La Roche

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Novartis AG
 - 9.6.1 Company overview
 - 9.6.2 Company snapshot
 - 9.6.3 Operating business segments
 - 9.6.4 Product portfolio
 - 9.6.5 Business performance
 - 9.6.6 Key strategic moves and developments
- 9.7 Pfizer Inc.
 - 9.7.1 Company overview
 - 9.7.2 Company snapshot
 - 9.7.3 Operating business segments
 - 9.7.4 Product portfolio
 - 9.7.5 Business performance
 - 9.7.6 Key strategic moves and developments
- 9.8 Sanofi
 - 9.8.1 Company overview
 - 9.8.2 Company snapshot
 - 9.8.3 Operating business segments
 - 9.8.4 Product portfolio
 - 9.8.5 Business performance
 - 9.8.6 Key strategic moves and developments
- 9.9 Sun Pharmaceutical Industries Ltd.
 - 9.9.1 Company overview
 - 9.9.2 Company snapshot
 - 9.9.3 Operating business segments
 - 9.9.4 Product portfolio
 - 9.9.5 Business performance
 - 9.9.6 Key strategic moves and developments
- 9.10 Teva Pharmaceutical Ltd.
 - 9.10.1 Company overview
 - 9.10.2 Company snapshot
 - 9.10.3 Operating business segments
 - 9.10.4 Product portfolio
 - 9.10.5 Business performance
 - 9.10.6 Key strategic moves and developments
- 9.11 Viartis (Mylan N.V.)
 - 9.11.1 Company overview
 - 9.11.2 Company snapshot
 - 9.11.3 Operating business segments
 - 9.11.4 Product portfolio
 - 9.11.5 Business performance

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 9.11.6 Key strategic moves and developments
- 9.12 Zydus Cadila
 - 9.12.1 Company overview
 - 9.12.2 Company snapshot
 - 9.12.3 Operating business segments
 - 9.12.4 Product portfolio
 - 9.12.5 Business performance
 - 9.12.6 Key strategic moves and developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Vertigo Treatment Market By Type (Peripheral Vertigo, Central Vertigo), By Treatment (Anticholinergics, Antihistamines, Others), By Distribution channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2031

Market Report | 2022-09-01 | 310 pages | Allied Market Research

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Cloud Access License	\$3456.00
	Business User License	\$5481.00
	Enterprise License	\$9450.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Date

2025-05-12

Signature



Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com